These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Conformational Diversity of the Helix 12 of the Ligand Binding Domain of PPARγ and Functional Implications. Batista MR; Martínez L J Phys Chem B; 2015 Dec; 119(50):15418-29. PubMed ID: 26598113 [TBL] [Abstract][Full Text] [Related]
6. PPARγ in Complex with an Antagonist and Inverse Agonist: a Tumble and Trap Mechanism of the Activation Helix. Frkic RL; Marshall AC; Blayo AL; Pukala TL; Kamenecka TM; Griffin PR; Bruning JB iScience; 2018 Feb; 5():69-79. PubMed ID: 30123887 [TBL] [Abstract][Full Text] [Related]
8. Insights into Dynamic Mechanism of Ligand Binding to Peroxisome Proliferator-Activated Receptor γ toward Potential Pharmacological Applications. Miyamae Y Biol Pharm Bull; 2021; 44(9):1185-1195. PubMed ID: 34471046 [TBL] [Abstract][Full Text] [Related]
9. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists. Liberato MV; Nascimento AS; Ayers SD; Lin JZ; Cvoro A; Silveira RL; Martínez L; Souza PC; Saidemberg D; Deng T; Amato AA; Togashi M; Hsueh WA; Phillips K; Palma MS; Neves FA; Skaf MS; Webb P; Polikarpov I PLoS One; 2012; 7(5):e36297. PubMed ID: 22649490 [TBL] [Abstract][Full Text] [Related]
10. The optimal corepressor function of nuclear receptor corepressor (NCoR) for peroxisome proliferator-activated receptor γ requires G protein pathway suppressor 2. Guo C; Li Y; Gow CH; Wong M; Zha J; Yan C; Liu H; Wang Y; Burris TP; Zhang J J Biol Chem; 2015 Feb; 290(6):3666-79. PubMed ID: 25519902 [TBL] [Abstract][Full Text] [Related]
12. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site. Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850 [TBL] [Abstract][Full Text] [Related]
13. Defining a conformational ensemble that directs activation of PPARγ. Chrisman IM; Nemetchek MD; de Vera IMS; Shang J; Heidari Z; Long Y; Reyes-Caballero H; Galindo-Murillo R; Cheatham TE; Blayo AL; Shin Y; Fuhrmann J; Griffin PR; Kamenecka TM; Kojetin DJ; Hughes TS Nat Commun; 2018 May; 9(1):1794. PubMed ID: 29728618 [TBL] [Abstract][Full Text] [Related]
14. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Burgermeister E; Schnoebelen A; Flament A; Benz J; Stihle M; Gsell B; Rufer A; Ruf A; Kuhn B; Märki HP; Mizrahi J; Sebokova E; Niesor E; Meyer M Mol Endocrinol; 2006 Apr; 20(4):809-30. PubMed ID: 16373399 [TBL] [Abstract][Full Text] [Related]
15. The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites. Waku T; Shiraki T; Oyama T; Maebara K; Nakamori R; Morikawa K EMBO J; 2010 Oct; 29(19):3395-407. PubMed ID: 20717101 [TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics simulations for human CAR inverse agonists. Jyrkkärinne J; Küblbeck J; Pulkkinen J; Honkakoski P; Laatikainen R; Poso A; Laitinen T J Chem Inf Model; 2012 Feb; 52(2):457-64. PubMed ID: 22233089 [TBL] [Abstract][Full Text] [Related]
17. Structural studies unravel the active conformation of apo RORγt nuclear receptor and a common inverse agonism of two diverse classes of RORγt inhibitors. Li X; Anderson M; Collin D; Muegge I; Wan J; Brennan D; Kugler S; Terenzio D; Kennedy C; Lin S; Labadia ME; Cook B; Hughes R; Farrow NA J Biol Chem; 2017 Jul; 292(28):11618-11630. PubMed ID: 28546429 [TBL] [Abstract][Full Text] [Related]
18. Ligand-Dependent Corepressor (LCoR) Is a Rexinoid-Inhibited Peroxisome Proliferator-Activated Receptor γ-Retinoid X Receptor α Coactivator. Shalom-Barak T; Liersemann J; Memari B; Flechner L; Devor CE; Bernardo TM; Kim S; Matsumoto N; Friedman SL; Evans RM; White JH; Barak Y Mol Cell Biol; 2018 May; 38(9):. PubMed ID: 29463649 [TBL] [Abstract][Full Text] [Related]
19. Definition of functionally and structurally distinct repressive states in the nuclear receptor PPARγ. Heidari Z; Chrisman IM; Nemetchek MD; Novick SJ; Blayo AL; Patton T; Mendes DE; Diaz P; Kamenecka TM; Griffin PR; Hughes TS Nat Commun; 2019 Dec; 10(1):5825. PubMed ID: 31862968 [TBL] [Abstract][Full Text] [Related]
20. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties. Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]